Today: 9 June 2026
Uber stock slips on Melius “Sell” call as robotaxi competition looms in 2026
5 January 2026
2 mins read

Uber stock slips on Melius “Sell” call as robotaxi competition looms in 2026

New York, January 5, 2026, 15:27 ET — Regular session

  • Uber shares fall about 2% after Melius cuts the stock to Sell and sets a $73 target
  • Analyst flags rising autonomous-vehicle competition as self-driving moves closer to wider deployment
  • Focus turns to Uber’s expected Feb. 4 earnings report for updates on margins and autonomy strategy

Uber Technologies, Inc. shares were down 1.9% at $81.30 in afternoon trading on Monday, after Melius Research downgraded the ride-hailing company to “sell” with a $73 price target. “Even with Uber’s position, AV competition is set to rise in 2026 and beyond,” Melius analyst Conor Cunningham wrote, referring to autonomous vehicles, or self-driving cars. Streetinsider

The call is landing at the start of a year when investors are trying to gauge how quickly robotaxis move from pilots into broader commercial service. That matters for Uber because self-driving fleets could change who controls pricing power and who keeps the larger share of each trip.

Uber’s core rides business hinges on scale and the “take rate” — the portion of rider spending the company keeps after paying drivers and incentives. If autonomous-vehicle operators push to own more of the economics, Uber’s cut can come under pressure, even if trip volumes rise.

Melius said Uber has tried to position itself as a “demand aggregator” — a platform that matches riders with vehicles — through partnerships and investments, but argued that greater competition could erode returns “whether Uber partners or not.” The firm also warned that a shift in growth expectations, or more standalone expansion announcements from the likes of Waymo and Tesla, could catch investors off guard. Investing

Uber has been leaning into alliances to stay central to autonomy without building the full stack itself. In October, Uber said it was working with Nvidia to accelerate robotaxi and autonomous delivery fleets using Nvidia’s AI architecture, with an ambition to scale its autonomous fleet to 100,000 vehicles over time starting in 2027.

The company has also built out a roster of autonomy-related deals. Uber said last year it would invest $300 million in EV maker Lucid as part of a plan to integrate more than 20,000 Lucid Gravity SUVs equipped with Nuro’s self-driving technology into a robotaxi rollout expected to begin in a major U.S. city in 2026, Reuters reported.

Uber’s decline weighed on sentiment across ride-hailing, with rival Lyft down 2.8%. The drop came even as the broader market held firmer, with the SPDR S&P 500 ETF up 0.7% and the Invesco QQQ Trust up 0.8%.

But the timing of robotaxi adoption remains a moving target, shaped by regulation, safety milestones and the economics of operating fleets at scale. Delays would push competitive pressure further out, while a faster-than-expected rollout could compress fees and intensify price competition.

Investors are now looking to Uber’s next earnings report for a clearer read on demand trends, profitability and any changes to its autonomy playbook. Nasdaq’s earnings calendar lists Feb. 4 as the expected reporting date for Uber’s quarterly results.

Stock Market Today

  • Wall Street Eyes Modest Gains as AI Stocks Rebound, Oil Prices Decline
    June 9, 2026, 10:03 AM EDT. Wall Street opened higher Tuesday with the S&P 500 climbing 0.6%, nearing its all-time high. The tech-heavy Nasdaq rose 0.7%, led by AI-related chipmakers like Micron Technology, which rebounded after recent sharp losses. Meanwhile, oil prices slipped, with Brent crude falling 1.6% to $92.83 a barrel amid easing geopolitical tensions. The decline in fuel costs boosted major U.S. airlines, which face soaring jet fuel expenses. Elevated oil prices continue to drive inflation and push yields higher, with the 10-year U.S. Treasury yield near 4.55%. Ahead this week, U.S. inflation data and a Federal Reserve policy meeting are in focus amid expectations of steady or higher interest rates. The mixed signals reflect ongoing uncertainty in markets amid global conflicts and inflation pressures.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
NuScale Power stock jumps 16% as House sets ‘New Nuclear Era’ hearing — what’s next for SMR
Previous Story

NuScale Power stock jumps 16% as House sets ‘New Nuclear Era’ hearing — what’s next for SMR

3.5 million hit by University of Phoenix data breach as school rolls out “credit for prior learning” push
Next Story

3.5 million hit by University of Phoenix data breach as school rolls out “credit for prior learning” push

Go toTop